MASIMO CORPORATION ($NASDAQ:MASI) announced their financial results for the second quarter of FY2023, which concluded on June 30 2023. Total revenue decreased by 19.5%, to USD 455.3 million, compared to the same quarter of the previous year. Net income also dropped 13.3%, to USD 15.7 million, year over year.
MASIMO CORPORATION has reported its second quarter earnings for fiscal year 2023. On Tuesday, the company’s stock opened at $122.1 and closed at $120.0, a decrease of 2.4% from the previous day’s closing price of 123.0. Overall, MASIMO CORPORATION’s Q2 earnings report was mostly positive, however, investors were disappointed by the lower than expected stock price. The company’s leadership is hopeful that the stock price will rebound in the near future as they continue to focus on product innovation and expanding into new markets. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Masimo Corporation. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Masimo Corporation. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Masimo Corporation. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Masimo Corporation are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Masimo Corporation Intrinsic Value
At GoodWhale, we conducted an analysis of MASIMO CORPORATION‘s wellbeing. Our proprietary Valuation Line yielded an estimated fair value of MASIMO CORPORATION’s shares of around $327.3. However, the present value observed for MASIMO CORPORATION’s stocks stands at $120.0, which is significantly lower than the calculated fair value. This implies that currently, MASIMO CORPORATION’s stocks appear to be undervalued by 63.3%. More…
Risk Rating Analysis
Star Chart Analysis
In the medical device industry, there is intense competition between Masimo Corp and its rivals Elekta AB, Essilorluxottica, and Compumedics Ltd. While all four companies offer innovative products and services, each has its own unique strengths and weaknesses. As a result, the competition between them is fierce, and it is often difficult for one company to gain a significant advantage over the others.
Despite a challenging year for the company, Elekta’s market cap has grown to 2.09B as of 2022. This is due in part to the company’s strong return on equity, which stands at 11.86%. Elekta is a leading provider of radiation therapy solutions for the treatment of cancer. The company’s products are used in over 6,000 hospitals and clinics around the world, and its solutions are backed by a team of over 3,000 employees.
– Essilorluxottica ($LTS:0OMK)
EssilorLuxottica is a French-Italian multinational corporation that designs, manufactures, and markets ophthalmic lenses, instruments, and equipment. The company has a presence in over 130 countries and employs more than 140,000 people. The company was formed in 2018 through the merger of Essilor International and Luxottica.
– Compumedics Ltd ($ASX:CMP)
Computedics Ltd is a technology company that provides computing and analytics solutions. The company has a market cap of 42.52M as of 2022 and a Return on Equity of 1.53%. Computedics Ltd provides computing and analytics solutions to businesses and organizations worldwide. The company offers a range of services, including data storage, cloud computing, data analysis, and security. Computedics Ltd is headquartered in Sydney, Australia.
Investors should take note of the drop in both revenue and net income reported by MASIMO CORPORATION for the second quarter of FY2023. Despite the 19.5% decrease in total revenue compared to the same quarter of the previous year, earnings were still positive at USD 15.7 million. It’s important to look at MASIMO’s competitive position in the market and how it is managing its costs during the pandemic to determine if it can maintain or increase its revenues and earnings going forward. Investors should keep an eye on this company and its financials to decide if it still may be a good investment option.